Skip to Content

Procomvax

Active Substance: polyribosylribitol phosphate from Haemophilus influenzae type b as PRP-OMPC / outer membrane protein complex of Neisseria meningitidis (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B) / adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae)
Common Name: haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine
ATC Code: J07CA
Marketing Authorisation Holder: Sanofi Pasteur MSD, SNC
Active Substance: polyribosylribitol phosphate from Haemophilus influenzae type b as PRP-OMPC / outer membrane protein complex of Neisseria meningitidis (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B) / adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae)
Status: Withdrawn
Authorisation Date: 1999-05-07
Therapeutic Area: Meningitis, Haemophilus Hepatitis B Immunization
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

PROCOMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age.

The marketing authorisation for Procomvax has expired following the marketing-authorisation holder’s decision not to apply for a renewal.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide